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Abstract
Background: Multiple Myeloma (MM) is a B cell neoplasm causing lytic or osteopenic bone abnormalities. Whole
body skeletal survey (WBSS), Magnetic resonance (MR) and 18F-FDG PET/CT are imaging techniques routinely
used for the evaluation of bone involvement in MM patients.
Aim: As MM bone lesions may present low 18F-FDG uptake; the aim of this study was to assess the possible added
value and limitations of 11C-Choline to that of 18F-FDG PET/CT in patients affected with MM.
Methods: Ten patients affected with MM underwent a standard 11C-Choline PET/CT and an 18F-FDG PET/CT
within one week. The results of the two scans were compared in terms of number, sites and SUVmax of lesions.
Results: Four patients (40%) had a negative concordant 11C-Choline and 18F-FDG PET/CT scans. Two patients
(20%) had a positive 11C-Choline and 18F-FDG PET/CT scans that identified the same number and sites of bone
lesions. The remaining four patients (40%) had a positive 11C-Choline and 18F-FDG PET/CT scan, but the two
exams identified different number of lesions. Choline showed a mean SUVmax of 5 while FDG showed a mean
SUVmax of 3.8 (P = 0.042). Overall, 11C-Choline PET/CT scans detected 37 bone lesions and 18F-FDG PET/CT
scans detected 22 bone lesions but the difference was not significant (P = 0.8).
Conclusion: According to these preliminary data, 11C-Choline PET/CT appears to be more sensitive than 18F-
FDG PET/CT for the detection of bony myelomatous lesions. If these data are confirmed in larger series of
patients, 11C-Choline may be considered a more appropriate functional imaging in association with MRI for MM
bone staging.
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Background
Multiple myeloma (MM) is a B cell neoplasm involving
bones in more than 80% of cases. Patients frequently
present with a single or multiple lytic bone lesions causing
bone pain, pathological fractures and hypercalcaemia [1-
5]. Bone abnormalities (lytic or osteopenic) are one of the
myeloma related organ dysfunction [6] and are responsi-
ble for low quality of life due to severe pain and high inci-
dence of fractures, and this is particularly dangerous if
located in the spine. The incidence of vertebral fractures
can be reduced with bisphosphonates that are now avail-
able in the therapeutic armamentarium of MM.
Bone lesions are usually evaluated with a spectrum of
imaging techniques, among which whole body skeletal
survey (WBSS) and spine and pelvis Magnetic Resonance
Imaging (MRI) are the most widely used. [7].
WBSS is known to be relatively insensitive for bone dam-
age detection as only those lesions characterized by a high
re-absorption rate (therefore appearing at a late stage) are
visible. Furthermore, WBSS, being a planar technique, can
easily underestimate bone involvement especially within
the spine where overlying tissues and rib cage hinder the
assessment of osteolysis. In addition, WBSS cannot distin-
guish between idiopathic osteoporotic vertebral fractures
and fractures due to MM and is not suitable to assess the
response to therapy.
Spine MRI, which was recently integrated in the Durie and
Salmon PLUS staging system, is proved to have a very
good sensitivity compared to WBSS especially at disease
onset [8-13]. The main limitations of MRI are the inability
to perform the scan in the presence of metallic prosthesis
or in case of severe claustrophobia. More importantly,
MRI is limited by the partial field of view that includes
only the spine and the pelvis. The skull, femura, humeri,
clavicles and ribs are often affected by lytic lesions but are
not included in MRI field of view. Whole Body MRI is now
available for a complete skeletal survey, but is rarely
employed on a routine basis.
Nuclear medicine imaging techniques were also used to
assess MM bone involvement. 99mTc-diphosphonate bone
scan and 67Ga-citrate scan were found to be unreliable due
to minimal osteoblastic activity and hypovascularity of
lesions. 99mTc-Sestamibi whole-body scan is more accu-
rate but the low spatial resolution limits the identification
of small lesions. Furthermore, the image interpretation
can be difficult due to the low tracer uptake within the
lesions and to the high physiological liver uptake that can
mask vertebral and right rib lesions. Therefore, nuclear
medicine tests have not gained widespread acceptance
[14-20].
In recent years, 18F-FDG PET and PET/CT were used as
possible novel strategy for MM evaluation. 18F-FDG PET is
a total body imaging technique that can detect both med-
ullary and extra-medullary lesions and has been found
useful for improving staging accuracy. Durie et al. in 2002
demonstrated that a negative 18F-FDG PET scan predicts
stable monoclonal gammopathy of indeterminate signifi-
cance (MGIS), identifies small lesions not detected by
WBSS, identifies extra-medullary lesions related to poor
prognosis and predicts an early relapse if it was positive
after therapy [21]. These results were confirmed by other
recent publications [22,23].
As stated before, 18F-FDG PET/CT is useful to correctly
stage MM with increased accuracy of bone lesion detec-
tion at disease onset. It is more sensitive than WBSS and
includes all the bones located out of the MRI field of view
[24].
Despite its sensitivity, the uptake of FDG assessed with the
maximum Standardized Uptake Value (SUVmax) can be
very low, sometimes even comparable to the SUVmax of a
benign lesion. Distinguishing between a benign lesion
and a low-metabolic MM lesion can therefore be difficult
to achieve.
11C-Choline is a radiolabelled PET tracer compound that
is clinically used for the evaluation of relapse of prostate
cancer. As with MM, prostate cancer does not show a sig-
nificant increase of 18F-FDG uptake, but is characterized
by a high 11C-Choline uptake [25]. Interestingly, a
recently published case report has shown increased 11C-
Choline uptake in a solitary plasmacytoma of bones [26].
The aim of our study was to assess the possible added
value and limitations of 11C-Choline compared with 18F-
FDG PET/CT in patients affected by MM.
Patients and methods
Between November 2004 and June 2006, we studied 10
patients (7 males and 3 females, mean age 58 years)
affected with MM. They underwent 11C-Choline PET/CT
and 18F-FDG PET/CT within one week (in most cases on
the same day). Four of the patients were evaluated at com-
pletion of initial therapy, 2 during follow-up and 4 at dis-
ease relapse. At disease onset, all the patients were in
Durie and Salmon stage III due to the presence of bone
lesions. For the 11C-Choline scan, all patients provided
informed consent for participation and anonymous pub-
lication of data.
Patients were injected with 5.3 MBq/Kg 11C-Choline iv
and scanned after an uptake period of 5 minutes. Data
acquisition was performed with a dedicated PET/CT tom-
ograph (GE, Discovery). Images were acquired in 2DWorld Journal of Surgical Oncology 2007, 5:68 http://www.wjso.com/content/5/1/68
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mode for 4 min per bed position, and attenuation correc-
tion was performed with a CT-based method (120 kV, 80
mA). Each PET/CT scan was read by two nuclear medicine
physicians and the reports agreed upon by consensus.
Each visible area of focal 11C-Choline uptake in bone
(excluding joints) was considered positive for a myeloma-
tous lesion. The SUVmax was calculated using the follow-
ing formula:
Tissue concentration (MBq/g)/injected dose (MBq)/body 
weight (g)
At least 4 hours after the 11C-Choline scan, the patients
were injected with 5.3 MBq/Kg 18F-FDG iv. None of the
patients was diabetic and the fasting time required for 11F-
FDG studies was at least 4 hours. The uptake time was 60–
90 minutes and the data acquisition was performed as for
the 11C-Choline scan.
11C-Choline scan results were compared to 18F-FDG scan
results in terms of number of lesions and SUVmax. The
SUVmax cut-off was 1.0 for 11C-Choline studies (the higher
uptake that we measured in normal bones) while all the
areas of focal uptake were interpreted as positive for mye-
loma in 18F-FDG scan unless they were at sites of known
accumulation. The latter include the kidneys and bladder,
gastrointestinal tract, and skeletal areas showing symmet-
ric joint uptake, especially within the shoulder girdle [21].
A mild diffuse increase in bone marrow activity was not
interpreted as positive for myeloma as it is a frequent find-
ing even in normal patients [27].
The CT attenuation correction map was not used as a ref-
erence diagnostic tool. Several bone lesions are normally
detected by PET at an early stage before these ere detecta-
ble with morphological imaging such as CT since density
alteration occurs much later than metabolic activity. Fur-
thermore, patients evaluated after being treated with a
specific therapy may present with persistent osteolytic
lesions on CT that do not show significant metabolic
activity any more.
All patients had at least one-year follow-up and under-
went several imaging procedures according to the clinical
decision and needs.
Statistical analysis
Statistical significance of differences in 11C-Choline SUV-
max and  18F-FDG SUVmax was determined using the Stu-
dent t Test. A two-tailed Mann-Whitney test was used to
compare the number of lesions detected with 11C-Choline
and 18F-FDG. The minimal level of significance was a P <
0.05.
Results
The mean number of lesions detected per patient in the
entire group was 3.7 for 11C-Choline and 2.2 for 18F-FDG
(P = 0.8). Considering only positive patients, the mean
number of lesions detected per patient was 7.4 for 11C-
Choline and 3.7 for 18F-FDG (Table 1).
In 4/10 patients (40%) there was a negative concordant
11C-Choline and 18F-FDG PET/CT scans. These findings
were consistent with clinical, laboratory and radiological
data indicating a complete remission at the time of imag-
ing. Of those four patients, three were evaluated after ther-
apy and one during follow-up.
In 2/10 patients (20%), evaluation was performed due to
suspicion of disease relapse and both 11C-Choline and
11F-FDG PET/CT scans were positive. In this group, both
techniques identified the same number and sites of bone
lesions.
The remaining 4/10 (40%) patients had a positive 11C-
Choline and 18F-FDG PET/CT scans, but the two tech-
niques identified a different number of lesions. In 3/4
patients,  11C-Choline identified more lesions compared
to 18F-FDG (8 vs. 1; 2 vs. 1; 10 vs. 2), while in 1/4 patient
18F-FDG detected a disease relapse within the pelvis that
was negative with 11C-Choline. Of these four patients, 2/
4 were evaluated due to suspicion of disease relapse, 1/4
following therapy and 1/4 during follow-up.
Table 2 shows the SUV max on a lesion by lesion basis for
11C-Choline scans and 18F-FDG scans (Table 2). 11C-
Choline showed a mean SUVmax of 5, while 18F-FDG
showed a mean SUVmax of 3.8 and the difference was sta-
tistically significant (p = .042). The SUVmax of visually
detectable lesions ranged from 1.1 to 19.2 for 11C-Choline
and from 2 to 13.7 for 18F-FDG. (Table 2).
Table 1: Number of bone lesions detected by 11C-Choline PET/
CT and 18F-FDG PET/CT patient by patient.
Patient 11C-Choline PET/CT 18F-FDG PET/CT
10 0
28 1
30 0
42 1
50 0
61 1 1 1
71 0 2
80 0
96 6
10 0 1
Total 37 22World Journal of Surgical Oncology 2007, 5:68 http://www.wjso.com/content/5/1/68
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Overall,  11C-Choline PET/CT scans detected 37 bone
lesions while 18F-FDG PET/CT scans detected 22 bone
lesions. This difference, however, was not statistically sig-
nificant and the P value was 0.8.
All the patients underwent a follow-up (1 month to 1 year
long) by repeating 18F-FDG PET/CT, MRI or CT. No false
positive findings were observed for the 18F-FDG or 11C-
Choline.
Discussion
Our preliminary results show that 11C-Choline PET/CT
detected more myelomatous lesions than 18F-FDG PET/
CT in our group of 10 patients. Although the difference
between the two tracers was not statistically significant in
terms of mean number of lesions detected, it is interesting
to note that 11C-Choline detected more lesions than 18F-
FDG in patient 2 and 7 (8 vs. 1 and 10 vs. 2), radically
changing these patients' management.
Table 2: Sites of lesions and SUVmax (11C-Choline and 18F-FDG) on a lesion by lesion basis. Bold: SUVmax of positive lesions. Non Bold: 
SUVmax of negative areas.
Patient 
number
Gender Age 
(years)
Disease 
stage
Therapy Indication 
to PET
Follow-up 
(months)
Confirma
tion of 
lesions
Number 
of 
lesions
Site of 
lesions
SUVmax 
Choline 
PET
SUVmax 
FDG PET
1 Male 61 IgA/lamda 
IIIA
Chemotherapy 
+ double 
autotranspalnt
Post-
therapy
19 Clinical 
follow-up
0
2 Male 55 IgA/lamba 
IIIA
Chemotherapy 
+ 
autotranspalnt
Suspect 
relapse
20 Clinical 
follow-up
1
2
3
4
5
6
7
8
pleura
soft tissues
humerus
humeral head
soft tissues
Ribs
D11
D12
7.0
4.2
5.1
6.0
3.0
4.7
2.5
2.7
1.0
2.0
1.3
1.9
0.8
1.5
1.0
1.0
3 Male 56 IgA/lamba 
IIIA
Chemotherapy 
+ 
autotranspalnt
Post-
therapy
8 Whole 
body X-
rays
0
4 Male 72 Solitary 
plasmacyto
ma of 
bones
Radiotherapy Follow-up 31 Magnetic 
resonance 
imaging
9
10
sacrum
D8–D10
5.6
2.0
2.8
1.0
5 Male 62 IgG/K IA Chemotherapy 
+ 
autotranspalnt
Follow-up 16 Clinical 
follow-up
0
6 Female 55 IgG/lamba 
IIIA
Chemo-
radiotherapy
Suspect 
relapse
16 Clinical 
follow-up
11
12
13
14
15
16
17
18
19
20
21
skull
scapula
clavicle
humerus
soft tissues
soft tissues
ribs
sternum
pelvis
sacrum
femur
1.3
4.2
2.8
3.6
5.5
4.5
6.5
4.0
7.5
6.0
5.7
3.5
9.7
6.6
4.5
13.7
12.3
6.5
3.0
4.9
5.8
3.1
7 Female 57 IgG/lamba 
IIIA
Chemotherapy 
+ 
autotranspalnt
Suspect 
relapse
16 FDG PET/
CT
22
23
24
25
26
27
28
29
30
31
scapula
sternum
clavicle
ribs
D4–D8
L4
L5
pelvis
sacrum
femur
1.3
1.8
2.4
3.0
2.2
2.3
2.2
2.9
1.1
3.0
1.0
3.4
1.2
2.5
1.0
1.7
1.9
0.9
1.6
1.7
8 Male 59 IgG/lamba 
IA
Chemotherapy Post-
therapy
8F D G  P E T /
CT
0
9 Female 49 IgA/K IIIA Chemotherapy 
+ 
autotranspalnt
Suspect 
relapse
8F D G  P E T /
CT
32
33
34
35
36
37
skull
clavicle
scapula
ribs
pelvis
femur
15.0
12.9
7.5
12.4
4.6
19.2
5.8
9.1
2.5
8.5
3.0
7.6
10 Male 53 Solitary 
plasmacyto
ma of 
bones
Radiotherapy Post-
therapy
1M a g n e t i c  
resonance 
imaging
38 sacrum 0.9 4.9
Mean 5.0 3.8
p 0.042World Journal of Surgical Oncology 2007, 5:68 http://www.wjso.com/content/5/1/68
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One patient turned out positive for several pleural lesions,
soft tissue involvement and bone lesions on 11C-Choline,
while 18F-FDG detected only the soft tissue lesion (Figure
1). Another patient turned out positive for several bone
lesions on 11C-Choline scan, while 18F-FDG detected only
a rib and a sternal lesion. On average, SUVmax was signifi-
cantly higher for 11C-Choline-positive lesions compared
to 11F-FDG-positive lesions (5.0 vs. 3.8), and this is an
unusual finding as 11C-Choline and 18F-FDG-positive
lesions behave in different ways.
It is not clear why myelomatous lesions demonstrate such
high 11C-Choline uptake compared to 18F-FDG. Sasagawa
et al, in a series of 16 patients affected by MM, demon-
strated that the serum levels of lysophospholipids were
significantly increased compared to normal patients [28].
Recently, Hideshima et al. showed that perifosine, an
alkylphospholipid, is active in-vitro against myelomatous
cells by inhibiting the phosphatidilinositol 3-kinase/Akt,
a mitogen-activated protein kinase which mediates MM
cell resistance to conventional therapies [29].
These data suggest that phospholipids are strongly
involved in the metabolism of myelomatous cells, espe-
cially in the modulation of intracellular growth signal
transduction pathways.
Choline is a small molecule precursor of phospholipids
and its uptake is increased in proliferating cells because it
is involved in membrane metabolism and growth
(increased during the mitotic process) that is significantly
altered in MM lesions.
The additional value of sensitive bone imaging techniques
in patients affected with MM is still not well defined, but
remains part of the routine assessment of disease activity.
However, recent studies suggest that the number of bone
lesions is related to the prognosis and that the functional
measurement of reduction in metabolism is a long term
predictive parameter of therapy response [30].
If this concept is confirmed in studies with larger number
of patients, the role of a sensitive technique that assesses
the whole body, such as 11C-Choline, could acquire
importance in patients affected by MM. In particular, it
may help to customise an early aggressive therapy in case
of multiple bone lesions to prevent a disease relapse or
loss of bone mineral density resulting in multiple frac-
tures.
The main disadvantage of 11C-Choline is the physiologi-
cal liver uptake that prevents detection of hepatic lesions
that may occur, though rarely, in MM patients. Further-
more, the role of 11C-Choline PET for the detection of
infiltrative pattern of the spine, not characterized by dis-
tinct focal lesions, needs further assessment as our small
series did not include any patient with such pattern on
MRI. This may prove to be useful as 18F-FDG PET is not
sensitive in the identification of infiltrative pattern of the
spine.
One patient had a positive 18F-FDG PET scan showing a
focal area of increased uptake located in the pelvis and a
negative 11C-Choline PET scan (Figure 2). The significance
of this mismatch is difficult to assess due to the short
period of follow up. It has been suggested that a lesion
with an initially negative 18F-FDG scan that shows uptake
at a later stage may have developed de-differentiation of
cancer cells and this may explain this discordant finding.
The prognosis in such cases is inversely correlated with the
SUVmax [31,32].
Conclusion
According to our preliminary data, 11C-Choline PET/CT
appears to be more sensitive than 18F-FDG PET/CT for the
detection of bone myelomatous lesions. If these data can
be confirmed in a larger series of patients, 11C-Choline
could be the most appropriate functional imaging in com-
bination with MRI for MM bone staging.
18F-FDG PET scan (A) and 11C-Choline PET scan (B) of a MM  patient Figure 1
18F-FDG PET scan (A) and 11C-Choline PET scan (B) of a MM 
patient. A) a small area of minimal uptake is detectable in 
dorsal soft tissues (black arrow), B) several areas of 
increased uptake are detected in bones, soft tissues and 
pleura (black arrows).World Journal of Surgical Oncology 2007, 5:68 http://www.wjso.com/content/5/1/68
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